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ABSTRACT Fluoroquinolones are an important class of modern and efficient antibacterial drugs with a broad 
spectrum of activity. Levofloxacin (the optically active form of ofloxacin) is one of the most promising fluoroqui-
nolone drugs, and its antibacterial activity is substantially higher than the activity of other drugs of the fluoro-
quinolone family. Earlier, in the Postovsky Institute of Organic Synthesis, UB RAS, an original method of levo-
floxacin synthesis was developed, and now the pilot batch of the drug is being prepared. Bacterial DNA gyrase is a 
specific target of fluoroquinolones; hence, the study of the enzyme-drug interaction is of theoretical and practical 
importance. Moreover, the parameters of DNA gyrase inhibition may serve as a criterion for drug quality. Here, 
we present the results of studying the interaction of DNA gyrase with a number of fluoroquinolones and their 
analogs: intermediates and semi-products of the levofloxacin synthesis, and also samples from the pilot batches of 
this drug. The importance of two structural elements of the levofloxacin molecule for the efficiency of the inhibi-
tion is revealed. The data obtained may be useful for the design of new drugs derived from levofloxacin.
KEYWORDS fluoroquinolones; levofloxacin; derivatives; bacterial DNA gyrase; enzymatic activity; inhibition.
INTRODUCTION
Fluoroquinolones are among the most important class-
es of effective antibacterial drugs with a broad spec-
trum of activity. they effectively compete with and 
can partly substitute cephalosporins and other antibio-
tics, which are widely used in clinical practice to cure 
infectious diseases [1–11]. the first fluoroquinolones 
(pefloxacin, ciprofloxacin, norfloxacin, and ofloxacin) 
appeared in the global pharmaceutical market in the 
early 1990s [1–6]. now, sales of ciprofloxacin amount 
to about 10 billion uS dollars, and novel promising 
drugs of this family, such as levofloxacin [12] (one of 
the enantiomers of ofloxacin) and moxifloxacin, have 
been developed. therefore, fluoroquinolones occupy 
an important place among the arsenal of antibiotics 
currently in use.
Fluoroquinolones are effective against a large number 
of diseases:   severe suppurative-septic infections, in-
cluding those of the respiratory tract, urinary tract, 
skin and soft tissues; bones and joints; liver and billiary; 
gastrointestinal tract, eyes and the central nervous 
system; and sexually transmitted infections [1–4]. the 
high efficiency of fluoroquinolones and wide spectrum 
of antibacterial activity is due to their ability to affect 
the reproduction of bacteria inhibiting bacterial topoi-
somerase II (DnA gyrase), an enzyme responsible for 
the breaking and restoration of the DnA double helix. It 
is of importance that the mechanism of fluoroquinolone 
action differs from that of the other groups of antibiotics 
(e. g., penicillin antibiotics, cephalosporins, and aminogly-
cosides), which enables the effective use of fluoroqui-
nolones for the treatment of infectious diseases caused 
by antibiotic-resistant strains [1–4].
Levofloxacin
One of the most effective drugs from the group of 
tricyclic fluoroquinolones is levofloxacin, which is an reSeArcH ArtIcLeS
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optically active from (S-isomer) of ofloxacin. the an-
tibacterial activity of levofloxacin is twice higher than 
the activity of racemic ofloxacin and 128 times higher 
than the activity of its R-antipode [13]. Levofloxacin is 
rightly referred to as a drug of the 21st century. this 
drug, at low doses, affects clinically important gram-
positive and atypical microorganisms. Besides, it exhi-
bits high activity towards many gram-negative bacte-
ria [12]. Original methods for the preparation of a family 
of fluoroquinolones and the corresponding synthetic 
precursors, including enantiomerically pure semi-prod-
ucts of levofloxacin synthesis, based on kinetic separa-
tion of optical antipodes using chiral reagents were re-
cently developed at the Postovsky Institute of Organic 
Synthesis, uB rAS, and the urals Federal university 
[5, 7, 11]. the impact of these studies, mainly the syn-
thesis of optically active levofloxacin and its analogs, 
has been confirmed by a series of publications [14–20], 
including an original and effective method for the pro-
duction of (S)-7,8-difluoro-2,3-dihydro-3-methyl-4H-
[1,4]-benzoxazine, which is a key semi-product of levo-
floxacin synthesis [14, 15].
currently, in the Postovsky Institute of Organic 
Synthesis, uB rAS, the design and synthesis of new 
fluoroquinolone derivatives and their analogs with an-
tibacterial activity are in progress. An important con-
stituent of these studies is the investigation of the in-
teraction of new compounds with DnA gyrase, which 
may be considered among the criterion for the purity 
of levofloxacin. In this paper, we present results of the 
investigation of the interaction of DnA gyrase with 
new fluoroquinolone derivatives, as well as with levo-
floxacin samples from the pilot batch.
EXPERIMENTAL
Materials
GyrA-pet19 and GyrB-pet19m plasmids contain-
ing genes encoding the A and B subunits of DnA gy-
rase were kindly provided by K.V. Severinov and 
I.S. Shkundina (Institute of Molecular Genetics, rAS) 
and were used as producers of DnA gyrase. the sub-
strates for the gyrase reaction (i. e., a relaxed plas-
mid pBr322 or pHOt) were purchased from topogen 
(uSA).
Isolation and Purification of DNA Gyrase
Escherichia coli rosetta (De3) {F- ompT hsdSB (rbmB-)
gal dcm lacY1 (DE3) pRARE6 (CmR)} (“novagen”, 
uSA) was used as the expression strain. the DnA gy-
rase subunits encoded by the plasmids contained six 
histidine residues at the N-terminus; the latter facili-
tated their isolation with affinity chromatography us-
ing ni-ntA-agarose.
the cells transformed with plasmids were grown 
overnight  in  5  ml  of  the  LB  medium  containing 
150 mg/l ampicillin (A150) and 15 mg/l chlorampheni-
col (c15) at 37°c. the cell pellet was obtained by cen-
trifugation and finally re-suspended in 250 ml of the 
fresh medium containing A150 and c15 and grown 
up to an optical density (OD550) of 0.5 at 37°c. then, 
isopropylthio-β-D-galactoside (IPtG) was added (final 
concentration 1 mM), and cultivation was continued for 
an additional 18 h at 17°c. cells were collected by cen-
trifugation at 4000 rpm for 20 min, washed with a Gte 
buffer (25 mM tris-Hcl, pH 7.6, 50 mM glucose, and 
10 mM eDtA), and kept frozen at –85°c. Furthermore, 
the cells were suspended in 15 ml of buffer A (20 mM 
tris-Hcl, pH 8.0, 500 mM nacl, 10% (v/v) glycerol, 1% 
(v/v) triton X-100, and 1 mM 2-mercaptoethanol), and 
protease inhibitors (1 mM phenylmethylsulfonyl fluo-
ride (PMSF) and 10 µg/ml aprotinin) were added. the 
suspension of cells was sonicated on ice and centrifuged 
for 15 min at 10000 g. the supernatant was applied on 
the column with ni-ntA-agarose (2 ml) equilibrated 
with buffer A. the column was subsequently washed 
with buffer A containing 10, 30, and 50 mM of imidazole 
(5 ml each), and the target proteins were eluted with 
the same buffer containing 200 mM of imidazole. the 
fractions containing gyrase A and gyrase B were dia-
lyzed against buffer A without triton X-100 and then 
against the same buffer containing 50% of glycerol. the 
yield and the purity of the enzymes were analyzed by 
12% polyacrylamide gel electrophoresis in accordance 
with the procedure described by Laemmli. the yield 
of gyrase A was 40 mg/l of the cell culture; gyrase B, 
around 60 mg/l. equivalent amounts of the thus-ob-
tained DnA gyrase subunits A and B were mixed, and 
the ali  quots at a volume of 30–50 µl could be stored at 
–80°c for several weeks without a significant loss of 
activity, while these enzyme samples remained active 
for only 2–3 days at –18° c.
Determination of the Activity of DNA Gyrase
the reaction mixture (30 µl) contained 35 mM tris-Hcl 
(pH 7.5), 24 mM Kcl, 4 mM Mgcl2, 1.4 mM AtP, 5 mM 
Dtt, 1.8 mM spermidine, and 0.1 mg/ml of a bovine se-
rum albumin. A mixture of DnA gyrase A and B subu-
nits (0.4 µg) and 0.25–0.5 µg of the substrate (relaxed 
plasmid pBr322) were added to the reaction probe. the 
reaction was performed for 60 min at 25°c (for multiple 
samples, 96-well plates were used). After the reaction 
was completed, the samples were extracted with an 
equal volume of chloroform (30 µl). then, 7 µl of the 
mixture containing 50% of sodium dodecyl sulfate, 25% 
of glycerol, and 0.25% of bromphenol blue were added 
to the aqueous phase. the mixture was applied on a 
1.2% agarose gel in tAe buffer (40 mM tris-acetate, 96 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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pH 8.0, 2 mM eDtA) and analyzed with electrophoresis 
(50 V, 2 h). the products were visualized under uV-
light after staining with ethidium bromide. the activity 
of the enzyme (%) was determined from the intensity 
of the band corresponding to the super-coiled form of 
plasmid pBr322 and estimated using the total Lab 
v2.01 software.
Inhibition of DNA Gyrase by Fluoroquinolones 
and Related Fluorine-Containing Heterocycles
the reaction mixture in a volume of 30 µl contained 
35 mM tris-Hcl (pH 7.5), 24 mM Kcl, 4 mM Mgcl2, 
1.4 mM AtP, 5 mM Dtt, 1.8 mM spermidine, 0.1 mg/ml 
bovine serum albumin, and a solution of levofloxacin or 
fluorine-containing heterocyclic derivatives (see be-
low) in DMSO (1-3 µl). An equal volume of DMSO was 
added to the control. the reaction was started upon 
addition of DnA gyrase (0.4 µg) and relaxed plasmid 
pBr322 (0.25–0.5 µg), which was used as a substrate, 
and performed as described above. calculations were 
made using the total Lab v2.01 program.
RESULTS AND DISCUSSION
the cellular target of fluoroquinolones is bacterial DnA 
gyrase, which consists of two subunits with Mr of 105 
and 95 kDa and encoded by the gyrA and gyrB genes, 
respectively. DnA gyrase has an A2B2-type tetramer-
ic structure [1–5]. Although this enzyme does not only 
break but also ligate the breaks in the DnA chains, nor-
mally, only one reaction is used to determine the enzyme 
activity in vitro; namely, the ability of the enzyme to 
produce a negative super coil form of the plasmid from 
the relaxed circular DnA. respectively, the substrate 
and the product can be separated and determined quan-
titatively using agarose gel electrophoresis.
the DnA gyrase from E. coli, which was used in this 
work, had high specific activity that enabled us to use 
these enzyme samples for testing the inhibitory activity 
of fluoroquinolones. First, levofloxacin (a left-rotating 
isomer of ofloxacin) with ee of about 99% was studied 
using ofloxacin (racemic form) as a control. Ofloxacin 
is well-known to clinicians as a fluoroquinolone of the 
first generation that has been in use in practical thera-
py for more than 15 years [1–4].
Inhibition of DnA gyrase by the above fluoroqui-
nolones are presented in Fig. 1. the Ic50 values calcu-
lated from the results of three independent experi-
ments were 2.50 ± 0.14 µg/ml and 6.20 ± 0.17 µg/ml for 
levofloxacin and ofloxacin, respectively, and they are 
in general agreement with the published data [7–10]. 
Moreover, the Ic50 ratios for these substances indicate 
the stereospecificity of DnA gyrase. the Ic50 value for 
the racemate (ofloxacin) is approximately twice higher 
than that for the individual stereoisomer (levofloxacin), 
which is roughly equal to its content in the racemic 
mixture.
Since the Ic50 value is widely used to describe the 
efficiency of the inhibition, it can be used to control 
the quality of levofloxacin. taking into account that 
only one isomer of ofloxacin efficiently inhibited the 
enzyme, one can also consider the Ic50 value as a crite-
rion of drug purity. Hence, biological activity, as well 
as chemical purity and the ee value, is considered to 
be an important characteristic of the quality of levo-
floxacin.
the structural formulas of levofloxacin, the key in-
termediates and semi-products of its pilot-scale syn-
thesis preformed in the Postovsky Institute of Organic 
Synthesis, uB rAS, are presented in Table 1.
All 19 samples of the levofloxacin taken from the pi-
lot batch had close Ic50 values (2.4–2.8 µg/ml); i.e., they 
are in close correlation, since the error of the methods 
used is about 20%, and they are in agreement with the 
data published for the sample of levofloxacin of 99% 
Ofloxacin, µg/ml                            Levofloxacin, µg/ml
C  0  1  3  10  30  0.1  0.3  1  3  10  30 
Fig. 1. Inhibition of DNA gyrase by levofloxacin and 
ofloxacin. Figures specify the concentrations of inhibitors 
in the reaction mixtures. C – control (plasmid without the 
enzyme).
IOS-K-001, µg/ml  IOS-E-01, µg/ml
0  1  3  10  0  1  10  30  C
Fig. 2. Inhibition of DNAgyrase by IOS-K-001 and IOS-
E-01. Figures specify the concentrations of inhibitors in 
the reaction mixtures. C – control (plasmid without the 
enzyme). Reaction conditions are described under “Ex-
perimental.”reSeArcH ArtIcLeS
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purity. Among the key intermediates and semi-prod-
ucts of levofloxacin synthesis, racemic benzoxazine 
(IOS-RS), enantiomerically pure benzoxazine (IOS-S), 
and the ester (IOS-E) exhibited no significant activity. 
the activity of the semi-product IOS-K was found to 
be lower by an order of magnitude as compared with 
that of levofloxacin (Fig. 2).
the comparison of the structural formulas for the 
semi-products IOS-E and IOS-K reveals that these 
samples differ only by the ethoxycarbonyl group in 
IOS-E, instead of the free carboxyl group in IOS-K. It 
is important to note that this difference is crucial for 
the activity; i. e., the substance possessing the carboxyl 
group shows significant inhibitory activity, while the 
ethoxycarbonyl derivative is practically inactive. this 
observation indicates the significant impact of the 
charged carboxyl group in the inhibition. these data 
are in accordance with the known mechanism of the 
interaction of fluoroquinolones with DnA gyrase and 
should be taken into account when designing novel and 
more effective inhibitors of the enzyme.
In this paper, the ability of several new fluoroqui-
nolone derivatives and fluorine-containing heterocy-
cles to inhibit DnA gyrase was also investigated. these 
substances were synthesized in the Postovsky Institute 
of Organic Synthesis, uB rAS. the results of the ex-
periments demonstrated that the majority of the stud-
ied compounds are inactive as depicted in Table 2. the 
only exceptions is fluoroquinolone EV-465, the activ-
ity of which is  lower than the activity of levofloxacin 
by approximately for two orders of magnitude and the 
known compounds from the fluoroquinolone group, i.e. 
IOS-NORFL_01 (norfloxacin) and IOS-PEFL_02 (pe-
floxacin) (Figs. 3, 4).
the compound IOS-NORFL_01 turned out to be a 
poor inhibitor, while substance IOS-PEFL_02 showed 
moderate activity, which was significantly lower than 
the activity of levofloxacin. It is important to note that 
these compounds differ only by the presence of an ad-
Table 1. Structural formulas of levofloxacin, intermediates, and semi-products of its synthesis
Structural formula Substance type of the 
substance code
Levofloxacin
(3S)-9-Fluoro-3-methyl-10-(4-methyl piperazine-1-il)-
7-oxo-2,3-dihydro-7H-pyrido[1,2,3-d,e]-benzoxazine-6-
carboxylic acid hemihydrate
Substance IOS-001 – 
IOS-019
(R,S)-7,8-Difluoro-3-methyl-2,3-dihydro-4H-benzo[b]
[1,4]-oxazine Intermediate IOS-rS-01, 
IOS-rS-02
(3S)-2,3-Dihydro-3-methyl-7,8-difluoro-1,4-benzoxazine Intermediate IOS-S-01, 
IOS-S-02
ethyl ester of (3S)-(-)-9,10-difluoro-3-methyl-7-oxo-
2,3-dihydro-7H-pyrido[1,2,3-d,e][1,4]-benzoxazine-6-
carboxylic acid 
Semi-product IOS-Е-01,
IOS-Е-02
(3S)-(-)-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-
pyrido[1,2,3-d,e][1,4]-benzoxazine-6-carboxylic acid Semi-product IOS-К-001,
IOS-К-002
       IOS-NORFL_01, µg/ml  IOS-PEFL_02, µg/ml 
К  0  1  3  10  30  0  3  10  30 
Fig. 3. Inhibition of DNA-gyrase by norfloxacin IOS-
NORFL_01 and pefloxacin IOS-PEFL_02. Figures specify 
the concentrations of inhibitors in the reaction mixtures. 
C – control (plasmid without the enzyme). Reaction con-
ditions are described under “Experimental.”98 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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Table 2. Inhibition activity of a series of fluoroquinolones and fluorine-containing heterocycles towards DNA gyrase
cODe/I50 µg/ml Structural formula cODe/I50 µg/ml Structural formula
eV-465
>30 eV-X149 Inactive
eV-591 Inactive eV-t150-c Inactive
eV-452-D Inactive eV-t156 Inactive
eV-313-D Inactive eV-t143-B Inactive
eV-572 Inactive eV-n51-B Inactive
eV-X58-A Inactive eV-n119-2 Inactive
IOS-nOrFL_01
>11
IOS-PeFL_02
2.8
3reSeArcH ArtIcLeS
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ditional methyl group in the piperazine ring of IOS-
PEFL_02. the introduction of the methyl group results 
in an increase in the efficiency of the inhibition by ap-
proximately an order of magnitude, and this observa-
tion is of importance for the future design of novel bio-
logically active fluoroquinolones.
IOS-NORFL_01
I50= > 11 µg/ml
IOS-PEFL_02
I50= 2.8 µg/ml
[Inhibitor], µg/ml
A
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Fig. 4. Determination of the I50 value for the compounds 
IOS-NORFL_01 and IOS-PEFL_02 (from the data shown 
in Fig. 3). The I50 value corresponds to the point at which 
dash lines intersect the X-axis.
the data obtained confirm that the degree of inhibi-
tion of bacterial DnA gyrase by levofloxacin and other 
fluoroquinolones is an important addition to physico-
chemical methods, when the quality of the synthesized 
drugs is controlled. using this method, the quality of 
19 samples from the pilot batch of levofloxacin was as-
sessed, along with eight intermediates and semi-prod-
ucts, as well as 14 new fluoroquinolone derivatives and 
their analogs.
Structure-activity relationship data outlined the im-
portance of the carboxyl group in the IOS-K structure, 
the etherification of which leads to the loss of the in-
hibitory activity, and the n-methyl group in compound 
IOS-PEFL, which is also essential for the activity. the 
data obtained should be considered during the design 
of novel drugs based on fluorine-containing heterocy-
cles.  
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